Brief: Ocumension Therapeutics Says Approval Received For Marketing Ot-703 In Hong Kong
20/12/2023 10:27
Dec 20 (Reuters) - Ocumension Therapeutics 1477.HK :
* APPROVAL RECEIVED FOR MARKETING OT-703 IN HONG KONG
* OT-703 OBTAINED APPROVAL FROM PHARMACY AND POISONS BOARD
OF HK
FOR REGISTRATION AS PHARMACEUTICAL PRODUCT IN HONG KONG
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application